全文获取类型
收费全文 | 46篇 |
免费 | 4篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 7篇 |
基础医学 | 8篇 |
口腔科学 | 1篇 |
临床医学 | 1篇 |
内科学 | 10篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
特种医学 | 3篇 |
外科学 | 1篇 |
预防医学 | 3篇 |
药学 | 2篇 |
肿瘤学 | 13篇 |
出版年
2022年 | 2篇 |
2021年 | 3篇 |
2020年 | 4篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 1篇 |
2012年 | 2篇 |
2011年 | 2篇 |
2010年 | 3篇 |
2009年 | 2篇 |
2008年 | 6篇 |
2007年 | 2篇 |
2006年 | 2篇 |
2004年 | 1篇 |
2003年 | 3篇 |
2002年 | 2篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
排序方式: 共有52条查询结果,搜索用时 15 毫秒
1.
2.
3.
Tobias Paul Seraphin MD Walburga Yvonne Joko-Fru MD Lucia Hämmerl MD Mirko Griesel MD Nikolaus Christian Simon Mezger MD Jana Cathrin Feuchtner MD Innocent Adoubi MD Marcel Dieu-Donné Egué BSc Nathan Okerosi Henry Wabinga MD Rolf Hansen BBA Samukeliso Vuma MD Cesaltina Lorenzoni PhD Bourama Coulibaly MD Sévérin W. Odzebe MD Nathan Gyabi Buziba MD Abreha Aynalem MD Biying Liu MPH Daniel Medenwald MD Rafael T. Mikolajczyk MD Jason Alexander Efstathiou MD Donald Maxwell Parkin MD Ahmedin Jemal PhD Eva Johanna Kantelhardt MD 《Cancer》2021,127(22):4221-4232
4.
Mirko Griesel Tobias P. Seraphin Nikolaus C.S. Mezger Lucia Hämmerl Jana Feuchtner Walburga Yvonne Joko-Fru Mazvita Sengayi-Muchengeti Biying Liu Samukeliso Vuma Anne Korir Gladys C. Chesumbai Sarah Nambooze Cesaltina F. Lorenzoni Marie-Thérèse Akele-Akpo Amalado Ayemou Cheick B. Traoré Tigeneh Wondemagegnehu Andreas Wienke Christoph Thomssen Donald M. Parkin Ahmedin Jemal Eva J. Kantelhardt 《The oncologist》2021,26(5):e807-e816
BackgroundCervical cancer (CC) is the most common female cancer in many countries of sub‐Saharan Africa (SSA). We assessed treatment guideline adherence and its association with overall survival (OS).MethodsOur observational study covered nine population‐based cancer registries in eight countries: Benin, Ethiopia, Ivory Coast, Kenya, Mali, Mozambique, Uganda, and Zimbabwe. Random samples of 44–125 patients diagnosed from 2010 to 2016 were selected in each. Cancer‐directed therapy (CDT) was evaluated for degree of adherence to National Comprehensive Cancer Network (U.S.) Guidelines.ResultsOf 632 patients, 15.8% received CDT with curative potential: 5.2% guideline‐adherent, 2.4% with minor deviations, and 8.2% with major deviations. CDT was not documented or was without curative potential in 22%; 15.7% were diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IV disease. Adherence was not assessed in 46.9% (no stage or follow‐up documented, 11.9%, or records not traced, 35.1%). The largest share of guideline‐adherent CDT was observed in Nairobi (49%) and the smallest in Maputo (4%). In patients with FIGO stage I–III disease (n = 190), minor and major guideline deviations were associated with impaired OS (hazard rate ratio [HRR], 1.73; 95% confidence interval [CI], 0.36–8.37; HRR, 1.97; CI, 0.59–6.56, respectively). CDT without curative potential (HRR, 3.88; CI, 1.19–12.71) and no CDT (HRR, 9.43; CI, 3.03–29.33) showed substantially worse survival.ConclusionWe found that only one in six patients with cervical cancer in SSA received CDT with curative potential. At least one‐fifth and possibly up to two‐thirds of women never accessed CDT, despite curable disease, resulting in impaired OS. Investments into more radiotherapy, chemotherapy, and surgical training could change the fatal outcomes of many patients.Implications for PracticeDespite evidence‐based interventions including guideline‐adherent treatment for cervical cancer (CC), there is huge disparity in survival across the globe. This comprehensive multinational population‐based registry study aimed to assess the status quo of presentation, treatment guideline adherence, and survival in eight countries. Patients across sub‐Saharan Africa present in late stages, and treatment guideline adherence is remarkably low. Both factors were associated with unfavorable survival. This report warns about the inability of most women with cervical cancer in sub‐Saharan Africa to access timely and high‐quality diagnostic and treatment services, serving as guidance to institutions and policy makers. With regard to clinical practice, there might be cancer‐directed treatment options that, although not fully guideline adherent, have relevant survival benefit. Others should perhaps not be chosen even under resource‐constrained circumstances. 相似文献
5.
6.
Paul Reinhold Walburga Audick Gerhard Bohn 《International journal of legal medicine》1981,87(1-2):75-84
Zusammenfassung Es wird über die Abflutung der Inhalationsnarkotika Halothan und Enfluran aus dem venösen Blut berichtet. Bei den gaschromatographisch durchgeführten Untersuchungen konnte keine Korrelation zwischen der Konzentration und der Abflutungszeit dieser Narkotika festgestellt werden, die Rüchberechungen der Blutspiegel mit forensisch ausreichender Sicherheit zulassen. 相似文献
7.
8.
9.
Weiss J Sos ML Seidel D Peifer M Zander T Heuckmann JM Ullrich RT Menon R Maier S Soltermann A Moch H Wagener P Fischer F Heynck S Koker M Schöttle J Leenders F Gabler F Dabow I Querings S Heukamp LC Balke-Want H Ansén S Rauh D Baessmann I Altmüller J Wainer Z Conron M Wright G Russell P Solomon B Brambilla E Brambilla C Lorimier P Sollberg S Brustugun OT Engel-Riedel W Ludwig C Petersen I Sänger J Clement J Groen H Timens W Sietsma H Thunnissen E Smit E Heideman D Cappuzzo F Ligorio C 《Science translational medicine》2010,2(62):62ra93
Lung cancer remains one of the leading causes of cancer-related death in developed countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions respond to treatment by epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibition, respectively, squamous cell lung cancer currently lacks therapeutically exploitable genetic alterations. We conducted a systematic search in a set of 232 lung cancer specimens for genetic alterations that were therapeutically amenable and then performed high-resolution gene copy number analyses. We identified frequent and focal fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell lung cancer (n = 155), but not in other lung cancer subtypes, and, by fluorescence in situ hybridization, confirmed the presence of FGFR1 amplifications in an independent cohort of squamous cell lung cancer samples (22% of cases). Using cell-based screening with the FGFR inhibitor PD173074 in a large (n = 83) panel of lung cancer cell lines, we demonstrated that this compound inhibited growth and induced apoptosis specifically in those lung cancer cells carrying amplified FGFR1. We validated the FGFR1 dependence of FGFR1-amplified cell lines by FGFR1 knockdown and by ectopic expression of an FGFR1-resistant allele (FGFR1(V561M)), which rescued FGFR1-amplified cells from PD173074-mediated cytotoxicity. Finally, we showed that inhibition of FGFR1 with a small molecule led to significant tumor shrinkage in vivo. Thus, focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients. 相似文献
10.
Ulrike Billmeier Walburga Dieterich Markus F Neurath Raja Atreya 《World journal of gastroenterology : WJG》2016,22(42):9300-9313
Anti-tumor necrosis factor(TNF) antibodies are successfully used in the therapy of inflammatory bowel diseases(IBD). However, the molecular mechanism of action of these agents is still a matter of debate. Apart from neutralization of TNF, influence on the intestinal barrier function, induction of apoptosis in mucosal immune cells, formation of regulatory macrophages as well as other immune modulating properties have been discussed as central features. Nevertheless, clinically effective anti-TNF antibodies were shown to differ in their mode-of-action in vivo and in vitro. Furthermore, the anti-TNF agent etanercept is effective in the treatment of rheumatoid arthritis but failed to induce clinical response in Crohn's disease patients, suggesting different contributions of TNF in the pathogenesis of these inflammatory diseases. In the following, we will review different aspects regarding the mechanism of action of anti-TNF agents in general and analyze comparatively different effects of each antiTNF agent such as TNF neutralization, modulation of the immune system, reverse signaling and induction of apoptosis. We discuss the relevance of the membranebound form of TNF compared to the soluble form for the immunopathogenesis of IBD. Furthermore, we review reports that could lead to personalized medicine approaches regarding treatment with antiTNF antibodies in chronic intestinal inflammation, by predicting response to therapy. 相似文献